Skip to main content

Table 2 Association of SUA levels with risk of MAFLD

From: Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study

Male

Serum uric acid [OR (95%CI)]

P for trend

Continuousa

Group 1 (< 4.0 mg/dL)

Group 2 (4.0–4.9 mg/dL)

Group 3 (5.0–5.9 mg/dL)

Group 4 (6.0–6.9 mg/dL)

Group 5 (≥ 7.0 mg/dL)

Model 1

1 (ref)

1.53 (1.21–1.93)

2.69 (2.06–3.52)

4.56 (3.58–5.82)

6.72 (5.19–8.70)

 < 0.001

1.57 (1.48–1.66)

Model 2

1 (ref)

1.12 (0.86–1.45)

1.44 (1.11–1.86)

2.03 (1.60–2.59)

2.46 (1.86–3.26)

 < 0.001

1.27 (1.20–1.35)

Model 3

1 (ref)

1.10 (0.84–1.45)

1.33 (1.01–1.75)

1.65 (1.27–2.14)

1.72 (1.25–2.37)

 < 0.001

1.17 (1.09–1.24)

  1. Model 1 was adjusted for demographic factors: age, sex, race/ethnicity, marital status, education level, and occupation type
  2. Model 2 was adjusted for model 1 plus lifestyle factors: smoking status, alcohol consumption, physical exercise, BMI, and eGFR
  3. Model 3 was further adjusted for model 2 plus biochemistry factors: triglyceride, total cholesterol, fasting glucose, CRP, and ALT
  4. aOR for 1 mg/dL SUA increase
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us